Condition:   Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: ranibizumab
Sponsors:   Johns Hopkins University;   Juvenile Diabetes Research Foundation
Recruiting - verified February 2010

Conditions:   Pulmonary Hypertension;   Sickle Cell Disease;   Thalassemia
Interventions:   Drug: L-Glutamine;   Drug: L-Glutamine
Sponsor:   Children's Hospital & Research Center Oakland
Recruiting - verified February 2010

Conditions:   Haemophilus Influenzae Type B Related Disease;   Pneumonia;   Meningitis;   Cellulitis;   Osteomyelitis;   Epiglottis
Interventions:   Biological: InfanrixTM;   Biological: GSK Biologicals' Haemophilus inluenzae type b vaccine (GSK 208108);   Biological: ActHIBTM;   Biological: PentacelTM;   Biological: PediarixTM;   Biological: PrevnarTM;   Biological: RotarixTM;   Biological: EngerixTM-B
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified March 2010

Condition:   Sickle Cell Disease
Interventions:   Other: High Demand / Low Infusion;   Other: PCA Dosing Plan
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Diabetes Mellitus, Type 2;   Acute Coronary Syndrome
Interventions:   Drug: Alogliptin;   Drug: Placebo
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Sickle Cell Disease;   Secretory Phospholipase A2;   sPLA2
Interventions:   Biological: Single blood transfusion;   Behavioral: Standard care
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2010

Condition:   Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions:   Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
Sponsors:   Regeneron Pharmaceuticals;   Bayer
Recruiting - verified February 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Factor XIII Deficiency
Intervention:   Biological: FXIII Concentrate Human
Sponsor:   CSL Behring
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Pazopanib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Invasive Aspergillosis
Intervention:   Drug: Voriconazole
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: aflibercept;   Drug: topotecan hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Tuberous Sclerosis
Interventions:   Drug: RAD001 (Everolimus);   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Fatigue;   Neuropathy;   Neurotoxicity
Interventions:   Dietary Supplement: acetyl-L-carnitine hydrochloride;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Back Pain
Interventions:   Drug: placebo;   Drug: tapentadol IR;   Drug: oxycodone IR
Sponsors:   Ortho-McNeil Janssen Scientific Affairs, LLC;   Grünenthal GmbH
Not yet recruiting - verified February 2010

Conditions:   Candidemia;   Candidiasis
Interventions:   Drug: anidulafungin;   Drug: fluconazole
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   GERD
Intervention:   Drug: Rabeprazole sodium
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Recruiting - verified February 2010

Condition:   Sarcoma
Interventions:   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: zoledronic acid;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Skin Diseases, Infectious
Interventions:   Drug: Daptomycin;   Drug: Vancomycin, Clindamycin or semi-synthetic Penicillins
Sponsor:   Cubist Pharmaceuticals
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Drug: pemetrexed disodium;   Drug: sunitinib malate
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Foot Ulcer, Diabetic
Interventions:   Other: Medical Food;   Other: Drink mix calorically similar to experimental product
Sponsor:   Abbott Nutrition
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: sunitinib malate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: cixutumumab;   Drug: capecitabine;   Drug: lapatinib ditosylate
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: idarubicin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Atrial Septal Defect
Intervention:   Device: AMPLATZER Septal Occluder
Sponsor:   AGA Medical Corporation
Recruiting - verified January 2009

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Hepatic Veno-Occlusive Disease
Intervention:   Drug: Defibrotide
Sponsor:   Gentium SpA
Recruiting - verified February 2010

Condition:   Pancreatic Cancer
Interventions:   Biological: cixutumumab;   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: letrozole;   Drug: tamoxifen citrate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Diseases
Interventions:   Biological: infliximab;   Drug: conventional systemic agents;   Biological: Biological therapies other than infliximab
Sponsor:   Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: Aflibercept (AVE0005);   Drug: Placebo
Sponsors:   Sanofi-Aventis;   Regeneron Pharmaceuticals;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Radiation: radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Lung Cancer;   Radiation Toxicity
Interventions:   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Aspergillosis
Interventions:   Drug: voriconazole;   Drug: anidulafungin;   Drug: voriconazole
Sponsors:   Pfizer;   Mycoses Study Group
Recruiting - verified February 2010

Conditions:   Staphylococcus Aureus;   Bacteremia;   Mediastinitis
Interventions:   Biological: V710;   Biological: Comparator: Placebo (unspecified)
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: paclitaxel
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Antithymocyte globulin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network
Recruiting - verified January 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Neurotoxicity;   Pain;   Peripheral Neuropathy;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Anemia
Intervention:   Drug: Deferasirox
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Apixaban;   Drug: Enoxaparin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Lung Cancer
Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:   Drug: maraviroc
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Other: internet-based intervention;   Procedure: assessment of therapy complications
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer
Intervention:   Drug: dasatinib
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: conventional surgery
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate;   Drug: temsirolimus
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Leukemia
Interventions:   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Lymphedema;   Perioperative/Postoperative Complications
Interventions:   Behavioral: exercise intervention;   Other: educational intervention;   Procedure: assessment of therapy complications;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV-1
Intervention:   Drug: TMC125
Sponsor:   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Pulmonary Complications;   Sarcoma
Interventions:   Biological: etanercept;   Drug: methylprednisolone
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain Death;   Organ Donor;   Pulmonary Edema
Interventions:   Drug: Albuterol;   Drug: Saline
Sponsors:   Vanderbilt University;   California Transplant Donor Network;   University of California, San Francisco
Recruiting - verified February 2010

Conditions:   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: cisplatin;   Drug: etoposide;   Drug: gemcitabine hydrochloride;   Drug: methylprednisolone
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: epratuzumab;   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Pain
Intervention:   Radiation: radiation therapy
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Radiation: iodine I 125;   Radiation: palladium Pd 103;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Drug: capecitabine;   Drug: fluorouracil;   Drug: oxaliplatin;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: therapeutic immune globulin;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009

Condition:   Melanoma (Skin)
Interventions:   Biological: recombinant interferon alfa;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Children's Oncology Group
Recruiting - verified March 2010